Adjuvant Radiation and Endocrine Therapy in Early-Stage Breast Cancer With Low Genomic Risk
In this cohort study of patients aged 50 to 69 years who underwent lumpectomy for early-stage breast cancer with ODX RS of 18 or below, we found significantly lower estimated LRR rates among those who completed at least 1 form of adjuvant therapy. For patients willing to accept a low absolute risk, but slightly higher relative risk of LRR with de-escalated therapy, ODX RS may be a valuable tool in selecting younger candidates for RT omission than current guidelines support.
Authors
- Beryl McCormick (ORCID: https://orcid.org/0000-0002-4550-0565)
- Lior Z. Braunstein (ORCID: https://orcid.org/0000-0002-5127-0217)
- Atif J. Khan (ORCID: https://orcid.org/0000-0001-8640-8530)
- Simon N. Powell (ORCID: https://orcid.org/0000-0002-8183-4765)
- Lillian A. Boe (ORCID: https://orcid.org/0000-0001-6279-9987)
- Michael B. Bernstein (ORCID: https://orcid.org/0000-0002-6677-4602)
- John Cuaron
- Hannah Yong Wen (ORCID: https://orcid.org/0000-0001-6794-5234)
- David Miller (ORCID: https://orcid.org/0000-0002-2785-6998)
- J. Isabelle Choi (ORCID: https://orcid.org/0000-0003-0897-6668)
- Boris Mueller
Institutions
- Memorial Sloan Kettering Cancer Center (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-09-17
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.32305
- Citations
- 2
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.87